NACDS Submits Comments to FDA on Expanding Access to Nonprescription Drugs
Comments emphasize the importance of coordinated policy and operational alignment to support affordable and seamless patient access.
NACDS Praises FDA Move to Delay Enforcement of Certain DSCSA “Track and Trace” Requirements Until November 27, 2024
This delay is an acknowledgement of a much needed delay – advocated by NACDS, along with supply chain and other pharmacy partners – to address technical and operational issues that had the potential to create supply chain disruptions and adversely impact patients’ access to needed medications.
Poll Shows Support for Extending Implementation Date for Prescription Drug “Track and Trace” to Prevent Drug-Shortage Risk 72% who support track and trace, and 70% of those who have experienced a medicine or health product shortage, back an extension of the DSCSA’s final implementation date
Seventy-two percent who support track and trace, and 70% of those who have experienced a medicine or health product shortage, back an extension of the DSCSA’s final implementation date.
Pharmacy and Pharmacist Groups Urge FDA to Adopt Phased Approach to Implementation of Enhanced Drug Distribution Security Requirements of Drug Supply Chain Security Act in Order to Prevent Interruptions to Patient Care “Specifically, we request FDA use its authority under the law for dispensers to comply with the EDDS requirements no earlier than February 27, 2026.”
“Specifically, we request FDA use its authority under the law for dispensers to comply with the EDDS requirements no earlier than February 27, 2026.”
In Case You Missed It: White House Celebrates End of X-Waiver Requirement, NACDS-Backed Law Change Included in December Omnibus Bill
A White House ceremony on Tuesday marked the end of the “X-waiver” requirement.
NACDS Welcomes FDA’s Action on Pharmacist-Prescribed COVID-19 Antivirals; Urges Next Steps for Lawmakers, CMS and Commercial Payers to Make Better Access a Reality
NACDS today welcomed the announcement by the U.S. Food and Drug Administration (FDA) that it revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), “to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.”
Senate Committee Moves FDA User Fee Bill with Five NACDS-Backed Provisions
Diverse NACDS-backed provisions would enhance patients’ access to OTC hearing aids and to biosimilar and generic medications, and would maintain flexibility in drug disposal options.
New York Times Pharmacy Story
Read the complete statement provided to The New York Times in January 2020.
